×
About 7,868 results

ALLMedicine™ Leukemias Center

Research & Reviews  2,230 results

Therapy Resistance Mechanisms in Hematological Malignancies.
https://doi.org/10.1002/ijc.34243
International Journal of Cancer; Hofmann WK, Trumpp A et. al.

Aug 14th, 2022 - Hematologic malignancies are model diseases for understanding neoplastic transformation and serve as prototypes for developing effective therapies. Indeed, the concept of systemic cancer therapy originated in hematologic malignancies and has guide...

Potent preclinical activity of FLT3-directed chimeric antigen receptor T cell immunothe...
https://doi.org/10.3324/haematol.2022.281456
Haematologica Niswander LM, Graff ZT et. al.

Aug 12th, 2022 - Chimeric antigen receptor (CAR) T cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), although relapse due to target antigen loss or downre...

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Aug 12th, 2022 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

A Study of Daratumumab
https://clinicaltrials.gov/ct2/show/NCT05438043

Aug 12th, 2022 - Daratumumab activity has been observed in multiple myeloma studies of daratumumab intravenous (IV) and subcutaneous (SC) monotherapy and combination therapy. Daratumumab (JNJ-54767414) is a first-in-class, human Immunoglobulin G1 kappa (IgG1 kappa...

Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: ...
https://doi.org/10.1016/j.cpcardiol.2022.101345
Current Problems in Cardiology; Janus SE, Heisler AC et. al.

Aug 11th, 2022 - Acute myelogenous leukemia (AML) is one of the most common leukemias experienced in adults and conveys significant morbidity and mortality. While the traditional anthracycline based treatments of AML involves cytarabine, developments in alternativ...

see more →

Guidelines  2 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  292 results see all →

Clinicaltrials.gov  232 results

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
https://clinicaltrials.gov/ct2/show/NCT05237986

Aug 12th, 2022 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...

A Study of Daratumumab
https://clinicaltrials.gov/ct2/show/NCT05438043

Aug 12th, 2022 - Daratumumab activity has been observed in multiple myeloma studies of daratumumab intravenous (IV) and subcutaneous (SC) monotherapy and combination therapy. Daratumumab (JNJ-54767414) is a first-in-class, human Immunoglobulin G1 kappa (IgG1 kappa...

Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02423057

Aug 9th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Aug 9th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...

Physical Activity to Improve Patient Reported Outcomes for Adults With Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT04552912

Aug 8th, 2022 - Rationale/Significance of Study: Acute leukemias (AL) are an aggressive and often debilitating cancer with increasing incidence among those with a prior history of cancer and older adults. Initial treatment is complex and even when remission is in...

see more →

News  388 results

Treating Older AML Patients and Managing Unique Toxicities
https://www.medscape.com/viewarticle/964537

Jul 20th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York City. It is my t...

Risky Business: Most Cancer Drugs Don't Reach the Market
https://www.medscape.com/viewarticle/977219

Jul 14th, 2022 - Only about 6% of cancer drugs tested in a phase 1 study in 2015 were ultimately approved by the US Food and Drug Administration (FDA) by 2021, a new analysis suggests. The researchers also found that about 8% of approved agents were subsequently t...

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma
https://www.onclive.com/view/dr-lin-on-treatment-updates-in-car-t-cell-therapy-in-myeloma

Apr 21st, 2022 - Yi Lin, MD, PhD, hematologist, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses treatment updates in CAR T-cell therapy in multiple myeloma. CD19-targeted CAR T-cell therapy has established a role in variou...

Some Leukemias Detectable Up to 16 Years Before Diagnosis?
https://www.medscape.com/viewarticle/971835

Apr 8th, 2022 - The preclinical phase of chronic lymphocytic leukemia (CLL) may be exist longer than previously thought, even in adverse-prognostic cases, as suggested by a sequencing analysis of blood samples obtained up to 22 years prior to CLL diagnosis. Previ...

Some leukemias detectable up to 16 years before diagnosis?
https://www.mdedge.com/hematology-oncology/article/253547/cll/some-leukemias-detectable-16-years-diagnosis
Sharon Worcester

Apr 7th, 2022 - The preclinical phase of chronic lymphocytic leukemia (CLL) may be exist longer than previously thought, even in adverse-prognostic cases, as suggested by a sequencing analysis of blood samples obtained up to 22 years prior to CLL diagnosis. Previ.

see more →

Patient Education  3 results see all →